Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans

NCT ID: NCT02974699

Last Updated: 2017-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is currently a critical gap in knowledge of how intestinal bacterial communities alter metabolic substrates available to the host thereby influencing central and enteric nervous system (CNS/ENS) neurotransmitter levels involved in regulating carbohydrate consumption in humans. Understanding these relationships is essential for developing strategies to improve blood glucose control and to reduce the risk of transitioning from prediabetes to type-2 diabetes (T2D). The investigators' long-term goal is to determine the biological underpinnings of behaviors that impact food intake and blood glucose control that contribute to the development of T2D. The objective of this proposal, which is an essential next step in attaining the investigators' long-term goals, is to determine how bacterial populations in the digestive system impact circulating tryptophan (TRP) and large neutral amino acid (LNAA) levels that regulate production of monoamine 5-hydroxytryptamine (5-HT, serotonin) in the ENS and in gastrointestinal system and the brain. The central hypothesis is that a reduced ratio of TRP producing (TRPp) to TRP consuming (TRPc) bacteria (decreased TRPp:TRPc ratio) in the gut will decrease TRP availability following a carbohydrate meal lowering the plasma TRP:LNAA ratio and resulting in less TRP for ENS/CNS production of 5HT. Further, dietary interventions that promote TRPp bacterial abundance within the gut will increase TRP availability to the host. The investigators will test the central hypothesis and, thereby, accomplish the overall objective for this project by pursuing the following specific aims: 1) Assess impact of divergent microbiota on plasma TRP:LNAA ratio in response to acute carbohydrate consumption, and 2) Assess the impact of dietary supplementation with resistant starch (RS) on gut microbiota and circulating TRP:LNAA ratio. During Aim 1, stool samples will be collected from healthy participants. Participants will be stratified based on gut TRPp:TRPc ratio and the response to an acute meal will be assessed by determining plasma TRP:LNAA ratios. During Aim 2 the capacity for 4-weeks of pre-biotic RS (Potato Starch) supplementation to increase the TRPp:TRPc bacterial ratio in the gut will be determined from stool samples. Additionally, plasma TRP:LNAA ratio following acute carbohydrate consumption before and after supplementation will be determined. The scientific contribution will be to determine the impact of RS on TRPp and TRPc bacteria abundance in the gut, and how bacterial populations impact circulating TRP:LNAA levels, that can impact ENS and CNS 5HT production in humans. This contribution will be significant because it will have direct translational implications for human diseases with altered 5HT signaling.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type II Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Potato Starch (Bob's Red Mill)

Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.

Group Type EXPERIMENTAL

Potato Starch (Bob's Red Mill)

Intervention Type DIETARY_SUPPLEMENT

Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.

Resource ThickenUp Pregelatinized Starch

Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.

Group Type PLACEBO_COMPARATOR

Pregelatinized Starch (Resource ThickenUp)

Intervention Type DIETARY_SUPPLEMENT

Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Potato Starch (Bob's Red Mill)

Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.

Intervention Type DIETARY_SUPPLEMENT

Pregelatinized Starch (Resource ThickenUp)

Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female
2. Age 18 - 65 years old
3. Non-Obese (BMI ≤ 30 kg/m2 and \>17 kg/m2 )

Exclusion Criteria

1. Urine toxicology positive,
2. Pregnant (female)
3. Alcohol intake 48 hours prior to studies,
4. Evidence of inherited disorders of lipid metabolism,
5. History of Cancer within the last 5 years,
6. Human immunodeficiency virus (HIV) antibody positive,
7. Patients with solid organ transplants,
8. Unstable angina or NY heart association class II failure or above,
9. Gastrointestinal disease specifically GI motility disorders,
10. Unstable neuropsychiatric disease including major depression/anxiety, eating disorder such as bulimia or anorexia,
11. End stage renal or hepatic disease,
12. Autoimmune disorders (e.g. SLE),
13. Prior bariatric surgery,
14. A history or current alcohol/substance abuse or nicotine containing products or illicit drugs of abuse during the preceding 6 months,
15. Treatment within one month with sedative hypnotic medications (benzodiazepines, barbiturates), or over the counter sleeping aids
16. Women: any selective estrogen receptor modulator or aromatase inhibitor Men:

androgen ablation/deprivation hormonal therapies
17. Any medical condition, which in the opinion of the investigator would make the patient unsuitable for recruitment, or could interfere with the patient participating in or completing the protocol
18. Any previous adverse events or allergic reactions to acetaminophen
19. Unwilling or unable to consent for the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wayne State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paul Burghardt

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wayne State University

Detroit, Michigan, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Paul R Burghardt, PhD

Role: CONTACT

3135770107

Katlin Chappelle, BS

Role: CONTACT

3135772716

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paul Burghardt

Role: primary

313-577-0107

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

110116M1F

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.